Resources

Get helpful information about MRD and M-inSight®

All
Articles
Documentation
Events
Posters
Publications
decoration
Publications
06/29/2023

Multiple Myeloma MRD Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow - Clin Chem. 2021

Publications
06/29/2023

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry - Blood Cancer J. 2023

Articles
06/29/2023

IMWG consensus criteria for response and minimal residual disease assessment in Multiple Myeloma - Lancet Oncol. 2016

Articles
06/29/2023

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma - Front Oncol. 2020

Articles
06/29/2023

Making clinical decisions based on measurable residual disease improves the outcome in Multiple Myeloma - J Hematol Oncol. 2021

Articles
06/29/2023

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration - Clin Cancer Res. 2021

Articles
06/29/2023

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications - Front Oncol. 2022

Articles
06/29/2023

Extramedullary disease in multiple myeloma: a systematic literature review - Blood Cancer J. 2022

Articles
06/29/2023

Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure! - Journal of Clinical Oncology, 2022

Articles
06/08/2023

Mass spectrometry for the evaluation of monoclonal proteins in MM and related disorders - Blood Cancer J. 2021

ABOUT M-inSight®

Ultra sensitive, Personalized MRD testing in Blood